kif18a

KIF18A-IN-13 (Compound 16) is an effective oral KIF18A inhibitor with in vivo anticancer properties. It can be utilized for the research of ovarian cancer.

KIF18A-IN-14 (Compound Example 81) is an inhibitor of KIF18A that exists in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit the viability of OVCAR-3 cells with IC50 values of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be utilized in tumor research, including studies on colon cancer, breast cancer, and lung cancer.

KIF18A-IN-15 (Compound Example 36) is a KIF18A inhibitor, available in two forms, EX36-A and its enantiomer EX36-B, both with an IC50 range of 0.01-0.1 μM. These compounds inhibit the viability of OVCAR-3 cells, with IC50 values of 0.01-0.1 μM for EX36-A and 0-0.01 μM for EX36-B. KIF18A-IN-15 is applicable in research on tumors, including colon, breast, and lung cancers.

KIF18A-IN-16 (Compound 15) is a polycyclic KIF18A inhibitor. It is applicable in research related to tumors, including colon cancer, breast cancer, and lung cancer.

KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A. This compound demonstrates significant anti-tumor properties.

KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.

KIF18A-IN-4 is a moderately potent, non-competitive KIF18A inhibitor of ATP and microtubule with an IC50 of 6.16 μM. It selectively acts on many mitotic kinesins and kinases, without directly affecting microtubule protein assembly, and shows anti-tumour effects.

KIF18A-IN-3 is an efficient KIF18A inhibitor (IC50 = 61nM) that induces mitotic arrest and increases the number of mitotic cells in tumor tissues. It can be used in tumor research.

KIF18A-IN-7 is an orally active inhibitor targeting KIF18A, demonstrating potent inhibition with an IC50 value of 9.4 nM against the microtubule-dependent ATPase activity of KIF18A.

KIF18A-IN-10 (Compound 24) is a potent inhibitor of KIF18A with an IC50 value of 3.8 nM. It exhibits anticancer activity with IC50 values below 100 nM in OVCAR3 and MDA-MB-157 cells.

(S)-AM-9022 is the S-enantiomer of AM-9022, which is a potent and selective KIF18A inhibitor with oral bioavailability, applicable in cancer research.

Sovilnesib is a kinesin-like protein KIF18A inhibitor. Sovilnesib can be used for the cancer research.

BTB-1 (NSC156750) is a novel small molecule inhibitor of the mitotic motor protein Kif18A.

AM-5308 is a kinesin KIF18A inhibitor that can be used to study cancer.

AM-9022 is a potent and selective KIF18A inhibitor, orally active and suitable for cancer research [1].

EX05, an effective KIF18A inhibitor, exhibits an IC50 of 8.2 nM and holds potential for cancer research applications.